Rakovina Financial Statements From 2010 to 2024

Stocks . Canada . 
Stock . Rakovina Therapeutics
RKV Stock  CAD 0.14  0.02  16.67%   
Rakovina Therapeutics financial statements provide useful quarterly and yearly information to potential Rakovina Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Rakovina Therapeutics financial statements helps investors assess Rakovina Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Rakovina Therapeutics' valuation are summarized below:
Market Capitalization
12.6 M
Earnings Share
(0.04)
There are over twelve available trending fundamental ratios for Rakovina Therapeutics, which can be analyzed over time and compared to other ratios. All traders should should check out Rakovina Therapeutics' recent fundamental trends against the trends from 2010 to 2024 to make sure the company is sustainable.
Check Rakovina Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rakovina Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 158.9 K, Interest Income of 21.7 K or Selling General Administrative of 706.8 K, as well as many indicators such as . Rakovina financial statements analysis is a perfect complement when working with Rakovina Therapeutics Valuation or Volatility modules.
  
This module can also supplement various Rakovina Therapeutics Technical models . Check out the analysis of Rakovina Therapeutics Correlation against competitors.

Rakovina Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Liabilities231174309
Slightly volatile
Common Stock16.4 M15.6 M4.7 M
Slightly volatile
Other Current Liabilities89.7 K85.5 K21.6 K
Slightly volatile
Total Current Liabilities103.3 K154.6 K31.9 K
Slightly volatile
Net Receivables30 K20.1 K9.3 K
Slightly volatile
Total Current Assets954.6 K632.5 K381.9 K
Slightly volatile
Total Assets5.3 M5.1 M8 M
Slightly volatile
Total Stockholder Equity4.9 M3.7 M7.8 M
Slightly volatile
Accounts Payable54.2 K80.4 K42.5 K
Slightly volatile
Cash414.5 K436.3 K2.4 M
Slightly volatile
Non Current Assets Total4 M4.5 M5.4 M
Slightly volatile
Common Stock Shares Outstanding76.9 M70.1 M70.3 M
Slightly volatile
Total Liabilities1.6 M1.5 M301.6 K
Slightly volatile
Net Invested Capital5.2 M5 M7.9 M
Slightly volatile
Capital Stock14.9 M13.6 M13.7 M
Slightly volatile
Net Working Capital454 K477.9 K2.5 M
Slightly volatile
Intangible Assets4 M4.5 M5.4 M
Slightly volatile
Net Debt717.4 K807.1 K878.8 K
Slightly volatile
Long Term Debt1.1 M1.2 M1.3 M
Slightly volatile

Rakovina Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income21.7 K22.4 K11.7 K
Slightly volatile
Selling General Administrative706.8 K810.4 K936.5 K
Slightly volatile
Research Development1.9 M1.7 M1.6 M
Slightly volatile
Total Operating Expenses2.9 M2.5 M2.5 M
Slightly volatile
Reconciled Depreciation544.5 K616.5 K443.3 K
Slightly volatile

Rakovina Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Cashflows From Investing Activities640 K720 K784 K
Slightly volatile
Other Cashflows From Financing Activities64.072.078.4
Slightly volatile
Depreciation348 K616.5 K155.2 K
Slightly volatile
Total Cash From Financing Activities1.1 M1.4 M533.4 K
Slightly volatile
Change To Netincome2.4 M2.7 M2.9 M
Slightly volatile
End Period Cash Flow414.5 K436.3 K304 K
Slightly volatile
Begin Period Cash Flow1 M896.8 K315.2 K
Slightly volatile
Stock Based Compensation202 K129.3 K335.1 K
Slightly volatile
Other Non Cash Items52.7 K55.5 K2.1 M
Slightly volatile

About Rakovina Therapeutics Financial Statements

Rakovina Therapeutics investors use historical fundamental indicators, such as Rakovina Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Rakovina Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Rakovina Stock Analysis

When running Rakovina Therapeutics' price analysis, check to measure Rakovina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rakovina Therapeutics is operating at the current time. Most of Rakovina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rakovina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rakovina Therapeutics' price. Additionally, you may evaluate how the addition of Rakovina Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY